72 related articles for article (PubMed ID: 20970976)
1. MK-0633, a potent 5-lipoxygenase inhibitor, in chronic obstructive pulmonary disease.
Bernstein JA; Liu N; Knorr BA; Smugar SS; Hanley WD; Reiss TF; Greenberg S
Respir Med; 2011 Mar; 105(3):392-401. PubMed ID: 20970976
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and tolerability of indacaterol 75 μg once daily in patients aged ≥40 years with chronic obstructive pulmonary disease: results from 2 double-blind, placebo-controlled 12-week studies.
Kerwin EM; Gotfried MH; Lawrence D; Lassen C; Kramer B
Clin Ther; 2011 Dec; 33(12):1974-84. PubMed ID: 22177371
[TBL] [Abstract][Full Text] [Related]
3. The efficacy and tolerability of MK-0633, a 5-lipoxygenase inhibitor, in chronic asthma.
Wasfi YS; Villarán C; de Tilleghem Cle B; Smugar SS; Hanley WD; Reiss TF; Knorr BA
Respir Med; 2012 Jan; 106(1):34-46. PubMed ID: 21945511
[TBL] [Abstract][Full Text] [Related]
4. Bronchodilatory effects of NVA237, a once daily long-acting muscarinic antagonist, in COPD patients.
Fogarty C; Hattersley H; Di Scala L; Drollmann A
Respir Med; 2011 Mar; 105(3):337-42. PubMed ID: 21144724
[TBL] [Abstract][Full Text] [Related]
5. Tiotropium administered by a pressurized metered dose inhaler (pMDI) and spacer produces a similar bronchodilator response as that administered by a Rotahaler in adult subjects with stable moderate-to-severe COPD.
Brashier B; Dhembare P; Jantikar A; Mahadik P; Gokhale P; Gogtay JA; Salvi SS
Respir Med; 2007 Dec; 101(12):2464-71. PubMed ID: 17719763
[TBL] [Abstract][Full Text] [Related]
6. Onset of effect of aclidinium, a novel, long-acting muscarinic antagonist, in patients with COPD.
Vestbo J; Vogelmeier C; Creemers J; Falques M; Ribera A; Gil EG
COPD; 2010 Oct; 7(5):331-6. PubMed ID: 20854047
[TBL] [Abstract][Full Text] [Related]
7. A 4-year trial of tiotropium in chronic obstructive pulmonary disease.
Tashkin DP; Celli B; Senn S; Burkhart D; Kesten S; Menjoge S; Decramer M;
N Engl J Med; 2008 Oct; 359(15):1543-54. PubMed ID: 18836213
[TBL] [Abstract][Full Text] [Related]
8. A randomized study of tiotropium Respimat Soft Mist inhaler vs. ipratropium pMDI in COPD.
Voshaar T; Lapidus R; Maleki-Yazdi R; Timmer W; Rubin E; Lowe L; Bateman E
Respir Med; 2008 Jan; 102(1):32-41. PubMed ID: 17996436
[TBL] [Abstract][Full Text] [Related]
9. [Efficacy of tiotropium bromide (Spiriva) in patients with chronic-obstructive pulmonary disease (COPD) of different severities].
Beeh KM; Beier J; Buhl R; Stark-Lorenzen P; Gerken F; Metzdorf N;
Pneumologie; 2006 Jun; 60(6):341-6. PubMed ID: 16761228
[TBL] [Abstract][Full Text] [Related]
10. [Comparison of tiotropium inhalation capsules and ipratropium metered dose inhaler in a randomized, double-blind, double-dummy, efficacy and safety study in patients with chronic obstructive pulmonary disease].
Zheng JP; Kang J; Cai BQ; Zhou X; Cao ZL; Bai CX; Zhong NS
Zhonghua Jie He He Hu Xi Za Zhi; 2006 Jun; 29(6):363-7. PubMed ID: 17045014
[TBL] [Abstract][Full Text] [Related]
11. The efficacy of tiotropium administered via Respimat Soft Mist Inhaler or HandiHaler in COPD patients.
van Noord JA; Cornelissen PJ; Aumann JL; Platz J; Mueller A; Fogarty C
Respir Med; 2009 Jan; 103(1):22-9. PubMed ID: 19022642
[TBL] [Abstract][Full Text] [Related]
12. COPD in young patients: a pre-specified analysis of the four-year trial of tiotropium (UPLIFT).
Morice AH; Celli B; Kesten S; Lystig T; Tashkin D; Decramer M
Respir Med; 2010 Nov; 104(11):1659-67. PubMed ID: 20724131
[TBL] [Abstract][Full Text] [Related]
13. Inhaled sodium pyruvate improved FEV1 and decreased expired breath levels of nitric oxide in patients with chronic obstructive pulmonary disease.
Votto JJ; Bowen JB; Barton RW; Thrall RS
J Aerosol Med Pulm Drug Deliv; 2008 Dec; 21(4):329-34. PubMed ID: 18800883
[TBL] [Abstract][Full Text] [Related]
14. Fast onset of effect of budesonide/formoterol versus salmeterol/fluticasone and salbutamol in patients with chronic obstructive pulmonary disease and reversible airway obstruction.
Lindberg A; Szalai Z; Pullerits T; Radeczky E
Respirology; 2007 Sep; 12(5):732-9. PubMed ID: 17875063
[TBL] [Abstract][Full Text] [Related]
15. Preoperative use of inhaled tiotropium in lung cancer patients with untreated COPD.
Kobayashi S; Suzuki S; Niikawa H; Sugawara T; Yanai M
Respirology; 2009 Jul; 14(5):675-9. PubMed ID: 19476597
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and safety of ipratropium bromide/albuterol delivered via Respimat inhaler versus MDI.
Zuwallack R; De Salvo MC; Kaelin T; Bateman ED; Park CS; Abrahams R; Fakih F; Sachs P; Pudi K; Zhao Y; Wood CC;
Respir Med; 2010 Aug; 104(8):1179-88. PubMed ID: 20172704
[TBL] [Abstract][Full Text] [Related]
17. Tolerability and efficacy of inhaled AZD4818, a CCR1 antagonist, in moderate to severe COPD patients.
Kerstjens HA; Bjermer L; Eriksson L; Dahlström K; Vestbo J
Respir Med; 2010 Sep; 104(9):1297-303. PubMed ID: 20466530
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety of the long-acting muscarinic antagonist GSK233705 delivered once daily in patients with COPD.
Bateman E; Feldman G; Kilbride S; Brooks J; Mehta R; Harris S; Maden C; Crater G
Clin Respir J; 2012 Oct; 6(4):248-57. PubMed ID: 22329914
[TBL] [Abstract][Full Text] [Related]
19. Effectiveness and tolerability of high-dose salmeterol in cystic fibrosis.
Hordvik NL; Sammut PH; Judy CG; Colombo JL
Pediatr Pulmonol; 2002 Oct; 34(4):287-96. PubMed ID: 12205570
[TBL] [Abstract][Full Text] [Related]
20. Effects of salmeterol on sleeping oxygen saturation in chronic obstructive pulmonary disease.
Ryan S; Doherty LS; Rock C; Nolan GM; McNicholas WT
Respiration; 2010; 79(6):475-81. PubMed ID: 19684384
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
